Ally Bridge Group (NY) LLC
13F Reported Value
ⓘ$113.1M
incl. option notional
Equity Holdings
ⓘ$77.6M
Option Notional
ⓘ$35.5M
$0 puts / $35.5M calls
Holdings
25
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Ally Bridge Group (NY) LLC disclosed 25 positions worth $113.1M in its Form 13F-HR for Q2 2026 — $77.6M in common stock plus $35.5M of put/call option positions (reported at underlying notional value, not premium at risk), led by $DFTX (Definium Therapeutics, Inc.) calls, followed by $ABVX and $NERV. During the quarter the fund opened 12 new positions and exited 14 — including a new stake in $DFTX and a full exit from $PRAX. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Ally Bridge Group (NY) LLC’s Form 13F-HR filing with the SEC under CIK 1822947.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- $18.8M400,000 sh
- —
Quality
$16.7M125,000 sh - —
Quality
$12.1M2,175,802 sh - —
Quality
$8.2M620,319 sh - $5.7M284,287 sh
- 40.8
Quality
$4.0M16,493 sh - 41.5
Quality
$3.8M140,000 sh - 26.4
Quality
$3.7M817,939 sh - —
Quality
$3.4M83,300 sh - —
Quality
$3.2M249,172 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Definium Therapeutics, Inc.$DFTXCALL | — | $18.8M | 400,000 |
 Abivax S.A.$ABVXCALL | — | $16.7M | 125,000 |
 Minerva Neurosciences, Inc.$NERV | — | $12.1M | 2,175,802 |
 ProMIS Neurosciences Inc.$PMN | — | $8.2M | 620,319 |
 First Tracks Biotherapeutics, Inc.$TRAX | — | $5.7M | 284,287 |
 Axsome Therapeutics, Inc.$AXSM | 40.8 | $4.0M | 16,493 |
 ASSEMBLY BIOSCIENCES, INC.$ASMB | 41.5 | $3.8M | 140,000 |
 Whitehawk Therapeutics, Inc.$WHWK | 26.4 | $3.7M | 817,939 |
 Edgewise Therapeutics, Inc.$EWTX | — | $3.4M | 83,300 |
 Climb Bio, Inc.$CLYM | — | $3.2M | 249,172 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Ally Bridge Group (NY) LLC's 25 positions.
Showing top 10 of 25 holdings.
Sector Allocation
Healthcare
$77.6M
Full Holdings — Ally Bridge Group (NY) LLC (Q2 2026)
All 25 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $DFTXCALL | Definium Therapeutics, Inc. | $18.8M | — | NEW | — |
| 2 | $ABVXCALL | Abivax S.A. | $16.7M | — | NEW | — |
| 3 | $NERV | Minerva Neurosciences, Inc. | $12.1M | 15.6% | +31% | — |
| 4 | $PMN | ProMIS Neurosciences Inc. | $8.2M | 10.5% | +50% | — |
| 5 | $TRAX | First Tracks Biotherapeutics, Inc. | $5.7M | 7.4% | NEW | — |
| 6 | $AXSM | Axsome Therapeutics, Inc. | $4.0M | 5.2% | NEW | 40.8 |
| 7 | $ASMB | ASSEMBLY BIOSCIENCES, INC. | $3.8M | 5.0% | NEW | 41.5 |
| 8 | $WHWK | Whitehawk Therapeutics, Inc. | $3.7M | 4.8% | +0% | 26.4 |
| 9 | $EWTX | Edgewise Therapeutics, Inc. | $3.4M | 4.4% | -48% | — |
| 10 | $CLYM | Climb Bio, Inc. | $3.2M | 4.2% | NEW | — |
| 11 |  $KURA | Kura Oncology, Inc. | $3.2M | 4.1% | NEW | 27.6 |
| 12 |  $CTMX | CytomX Therapeutics, Inc. | $2.9M | 3.8% | -14% | 8.7 |
| 13 |  $AVTX | Avalo Therapeutics, Inc. | $2.8M | 3.6% | NEW | 11.7 |
| 14 |  $PALI | PALISADE BIO, INC. | $2.6M | 3.3% | NEW | — |
| 15 |  $SLDB | Solid Biosciences Inc. | $2.6M | 3.3% | -67% | — |
| 16 |  $ANTX | AN2 Therapeutics, Inc. | $2.5M | 3.3% | +0% | — |
| 17 |  $URGN | UroGen Pharma Ltd. | $2.5M | 3.3% | -66% | — |
| 18 |  $CATX | Perspective Therapeutics, Inc. | $2.5M | 3.3% | -20% | — |
| 19 |  $IDYA | IDEAYA Biosciences, Inc. | $2.5M | 3.2% | NEW | 36.1 |
| 20 |  $IVA | Inventiva S.A. | $2.4M | 3.1% | -15% | — |
| 21 |  $ALMS | ALUMIS INC. | $2.2M | 2.8% | -54% | 7.1 |
| 22 |  $OVID | Ovid Therapeutics Inc. | $1.7M | 2.2% | -78% | 26.4 |
| 23 |  $EPRX | EUPRAXIA PHARMACEUTICALS INC. | $1.7M | 2.1% | -62% | — |
| 24 |  $IBIO | iBio, Inc. | $682,757 | 0.9% | NEW | 10.4 |
| 25 |  $TRAW | Traws Pharma, Inc. | $663,033 | 0.8% | NEW | — |
New Positions (12)
$DFTXCALL Definium Therapeutics, Inc.$18.8M$ABVXCALL Abivax S.A.$16.7M$TRAX First Tracks Biotherapeutics, Inc.$5.7M$AXSM Axsome Therapeutics, Inc.$4.0M$ASMB ASSEMBLY BIOSCIENCES, INC.$3.8M$CLYM Climb Bio, Inc.$3.2M$KURA Kura Oncology, Inc.$3.2M$AVTX Avalo Therapeutics, Inc.$2.8M$PALI PALISADE BIO, INC.$2.6M$IDYA IDEAYA Biosciences, Inc.$2.5M$IBIO iBio, Inc.$682,757$TRAW Traws Pharma, Inc.$663,033Exited Positions (14)
$PRAX Praxis Precision Medicines, Inc.
$SLNO SOLENO THERAPEUTICS INC$SLNOPUT SOLENO THERAPEUTICS INC
$CMPS COMPASS Pathways plc
$TARS Tarsus Pharmaceuticals, Inc.
$CMPXCALL Compass Therapeutics, Inc.
$QURECALL uniQure N.V.$ABVX Abivax S.A.
$CAPR CAPRICOR THERAPEUTICS, INC.
$MAZECALL Maze Therapeutics, Inc.
$IKT Inhibikase Therapeutics, Inc.
$REPLCALL Replimune Group, Inc.
$RLMD RELMADA THERAPEUTICS, INC.
$KPTICALL Karyopharm Therapeutics Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Ally Bridge Group (NY) LLC including:
Track Ally Bridge Group (NY) LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Ally Bridge Group (NY) LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Ally Bridge Group (NY) LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Ally Bridge Group (NY) LLC (SEC CIK: 1822947), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Ally Bridge Group (NY) LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.